The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...

A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden’s ...

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, ...

Discover the latest breakthroughs in oncology, including pivotal FDA decisions, promising therapies, and new treatment options for multiple myeloma and ovarian cancer.

Investing.com -- GSK (LON: GSK) shares dropped more than 6% on Friday after a U.S. Food and Drug Administration advisory panel voted against the benefit-risk profile of Blenrep (belantamab ...

Gail Whiteford wants to raise awareness of the symptoms she suffered to avoid the same happening to other people.

After hearing she had two months to live, Middlesex Township resident Wanda Stouffer learned she'd qualified for a treatment ...

Transmembrane proteins (TPs), also referred to as ‘integral membrane proteins’, make up between 70 % and 80 % of the total ...

Carmen Phaneuf has completed multiple triathlons, gone hiking in France, and skied in Iceland, but during all of these adventures, cancer was looming like a storm cloud. Phaneuf, of Little Falls, has ...

Rapid advances have revolutionized the treatment of multiple myeloma ... with immunomodulatory drugs, proteasome inhibitors, CAR T-cell therapies, and monoclonal and bispecific antibodies. In addition ...

Nadine Poormon, diagnosed with multiple myeloma in 2017, participated in a trial that helped Carvykti gain FDA approval. She had tried several drugs before Carvykti without success.